Table 3.
Tolerance times (in minutes) for each subject and statistical analysis within groups for team C
| Subject | Precompetition training |
Competition |
Postcompetition |
||
|---|---|---|---|---|---|
| Week 1 | Week 2 (morphine) | Week 3 (morphine) | Week 4 (placebo) | Week 5 (control) | |
| 1 | 15 | 25 | 27 | 22 | 13 |
| 2 | 14 | 22 | 23 | 21 | 13 |
| 3 | 18 | 27.5 | 27 | 24 | 16.5 |
| 4 | 11.5 | 18 | 21 | 16.5 | 13 |
| 5 | 11 | 19.5 | 19 | 17.5 | 10.5 |
| 6 | 17.5 | 28.5 | 27.5 | 24 | 15 |
| 7 | 16 | 28 | 29 | 26.5 | 14 |
| 8 | 11.5 | 17.5 | 20.5 | 18 | 11 |
| 9 | 13 | 22 | 21.5 | 19.5 | 12 |
| 10 | 10.5 | 20 | 20 | 19 | 11 |
| Mean ± SD | 13.8 ± 2.7 | 22.8 ± 4.2 | 23.5 ± 3.7 | 20.8 ± 3.3 | 12.9 ± 1.9 |
Repeated-measures ANOVA across the 5 weeks: F(4,36)= 148.791; p < 0.001. Student–Newman–Keuls: week 3 versus week 1, q(36)=23.509, p < 0.001; week 2 versus week 4, q(36)=4.822, p < 0.05; week 3 versus week 4, q(36)=6.631, p < 0.01; week 2 versus week 5, q(36)=23.871, p < 0.001; week 3 versus week 5, q(36)=25.679, p < 0.001; week 4 versus week 1, q(36)=16.878, p < 0.001; week 2 versus week 1, q(36)=21.701, p < 0.001; week 4 versus week 5, q(36)=19.049, p < 0.001. The other comparisons are not significant.